palmitoyl tripeptide-5
Pal-KVK, N-palmitoyl-L-lysyl-L-valyl-L-lysine, Pal-Lys-Val-Lys
Palmitoyl tripeptide-5 is a synthetic lipopeptide of lysine-valine-lysine with a palmitic acid tail, sold on the claim that it imitates thrombospondin-1 and thereby activates latent transforming growth factor beta to increase collagen. The thrombospondin-1 biology it invokes is real and well mapped, but the sequence responsible for that biology is not the sequence in this ingredient, and no published study tests the claim for the peptide on its own.
Mechanism
The rationale rests on genuine matrix biology. Latent TGF-beta is held inactive by its latency-associated peptide (LAP). Schultz-Cherry and Murphy-Ullrich showed the type 1 repeats of thrombospondin-1 activate latent TGF-beta, and mapping identified the tetrapeptide Lys-Arg-Phe-Lys (KRFK) within those repeats as the activating sequence, working by binding the Leu-Ser-Lys-Leu sequence of LAP and displacing it. Ribeiro and colleagues confirmed the direct KRFK-LAP interaction, and Yee and colleagues showed the type 1 repeats activate TGF-beta in vivo.
The difficulty is the sequence. Palmitoyl tripeptide-5 is Lys-Val-Lys. It shares two lysines with KRFK but lacks the arginine and the phenylalanine, and it is a tripeptide rather than the characterised tetrapeptide. No published paper reports that Lys-Val-Lys, palmitoylated or otherwise, binds LAP, displaces LSKL, activates latent TGF-beta, or increases collagen in any system. The palmitoyl chain performs the usual function of making a highly cationic, water-soluble tripeptide lipophilic enough to enter the stratum corneum. Readers should treat the thrombospondin mechanism as an inference drawn from adjacent literature, not as a demonstrated property of this molecule.
What the research shows
The thrombospondin-1 literature is solid. The 1994 Journal of Biological Chemistry paper established that the type 1 repeats of thrombospondin-1 activate latent TGF-beta; the 1995 companion narrowed activation to KRFK and identified LSKL within LAP as its target; Ribeiro and colleagues demonstrated the direct interaction in 1999; and Yee and colleagues showed the effect operates in vivo in 2004. None of it involves Lys-Val-Lys, and the ingredient borrows the credibility of thrombospondin-1 pharmacology without having demonstrated that it shares the relevant pharmacology.
For the ingredient itself, what exists is limited and always combinatorial. Avcil and colleagues reported that hyaluronic acid microneedle patches containing arginine/lysine polypeptide, acetyl octapeptide-3, palmitoyl tripeptide-5, adenosine and seaweed extracts produced a 25.8% decrease in fine lines and wrinkles, a 15.4% improvement in hydration, and 14.2% and 12.9% increases in dermal density and thickness over 12 weeks, with excellent tolerability, but with no control arm and no way to attribute any of it to the peptide. The ingredient also appears in a review of synthetic peptides for sensitive skin and in formulation papers on supramolecular carriers. There are no fibroblast collagen data, no penetration data and no controlled trial for the compound.
Evidence assessment
Preclinical only
The draft this record corrects claimed PubMed returns nothing for the compound; that is false and was checked directly. Four records mention it, of which one is a genuine clinical study: Avcil and colleagues (2020) ran a 12-week monocentric study of hyaluronic acid microneedle patches whose test product contained palmitoyl tripeptide-5 alongside four other actives. That study is nonetheless uncontrolled, tests five actives at once, uses a microneedle delivery device rather than topical application, and was industry-run, so it cannot lift the tier. There is still no published receptor-binding, fibroblast, animal or penetration study of the peptide itself, and no study testing the TGF-beta activation claim. 'Preclinical' therefore stands, but as a description of a near-empty dossier rather than a laboratory one.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study Preclinical only
Fine lines and wrinkles decreased 25.8%, hydration improved 15.4%, dermal density and thickness increased 14.2% and 12.9%; excellent tolerability with no primary or cumulative skin reactions.
Usage of Synthetic Peptides in Cosmetics for Sensitive Skin Preclinical only
Catalogues palmitoyl tripeptide-5 among synthetic cosmetic peptides and their claimed activities; a secondary source, not primary evidence.
The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta Preclinical only
Localised TGF-beta activating capacity to the type 1 repeats of thrombospondin-1.
Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1 Preclinical only
Identified Lys-Arg-Phe-Lys (KRFK) as the thrombospondin-1 sequence that activates latent TGF-beta, and Leu-Ser-Lys-Leu within the latency-associated peptide as its binding partner.
The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta Preclinical only
Demonstrated direct interaction between the KRFK activation sequence and the latency-associated peptide, confirming the displacement mechanism.
Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta Preclinical only
Confirmed that thrombospondin-1 type 1 repeats activate TGF-beta with biological consequence in vivo.
Safety
No adverse effects have been reported for cosmetic use, and palmitoyl oligopeptides have been assessed as a class by the Cosmetic Ingredient Review without concerns at use levels. Avcil and colleagues reported no primary or cumulative skin reactions in their microneedle study, though the peptide was one of five actives. Two general points are worth flagging. Highly cationic lipopeptides can be membrane-active at sufficient concentration; cosmetic use levels are far below any such threshold, but this is why concentration matters. And if an agent genuinely did activate dermal TGF-beta, that would not be unambiguously desirable. Sustained TGF-beta signalling is central to fibrosis and hypertrophic scarring. Since there is no evidence the ingredient does this, the point is theoretical, but it illustrates why a mechanism should not be assumed benign because it is marketed as anti-ageing. Topical cosmetic use only; not evaluated for injection; no human pregnancy or lactation data.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Permitted as a cosmetic ingredient under the UK Cosmetics Regulation (retained Regulation (EC) No 1223/2009); not listed in any prohibited or restricted annex. Requires a Cosmetic Product Safety Report and responsible person. No MHRA medicines authorisation. |
| United States | Not an FDA-approved drug and not covered by an OTC drug monograph; marketed as a cosmetic ingredient. Cosmetic ingredients are not pre-approved under the FD&C Act as amended by the Modernization of Cosmetics Regulation Act 2022, but structure-or-function claims can render a product an unapproved drug. |
| WADA (sport) | Not named on the WADA Prohibited List. Topical cosmetic use raises no anti-doping issue. |
Questions
There is no published evidence that it does. The thrombospondin-1 sequence that activates latent TGF-beta is Lys-Arg-Phe-Lys. Palmitoyl tripeptide-5 is Lys-Val-Lys, a different and shorter sequence, and no study has tested whether it binds the latency-associated peptide or activates the cytokine.
Very little, but not none. A handful of PubMed records mention it, including one 12-week clinical study of a microneedle patch that contained it alongside four other actives. There is no study of the peptide on its own: no receptor work, no fibroblast collagen data, no animal work and no penetration study.
Not straightforwardly. TGF-beta drives collagen synthesis, but sustained TGF-beta signalling is also the central pathway in fibrosis and hypertrophic scarring. A genuine dermal TGF-beta activator would need careful evaluation rather than being assumed beneficial. Since there is no evidence this ingredient does that, the concern remains theoretical.
There is no reported harm from cosmetic use, and palmitoyl oligopeptides have been reviewed as a class without safety concerns at use levels. The realistic issue with this ingredient is not risk but the near-absence of evidence that it does anything attributable to the peptide itself.